Cargando…

Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies

OBJECTIVES: China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be esta...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Wenchuan, Cheng, Xiaoli, Wang, Haitao, Zang, Xiao, Chen, Tingting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655525/
https://www.ncbi.nlm.nih.gov/pubmed/34880019
http://dx.doi.org/10.1136/bmjopen-2021-052682
_version_ 1784612093047078912
author Shi, Wenchuan
Cheng, Xiaoli
Wang, Haitao
Zang, Xiao
Chen, Tingting
author_facet Shi, Wenchuan
Cheng, Xiaoli
Wang, Haitao
Zang, Xiao
Chen, Tingting
author_sort Shi, Wenchuan
collection PubMed
description OBJECTIVES: China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be established. We summarised evidence on the cost-effectiveness of HPV vaccine in China. DESIGN: Systematic review and narrative synthesis DATA SOURCES: PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang Data were searched through 2 January 2021 ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Cost-effectiveness studies using a modelling approach focusing on HPV vaccination interventions in the setting of China were included for review. DATA EXTRACTION AND SYNTHESIS: We extracted information from the selected studies focusing on cost-effectiveness results of various vaccination programmes, key contextual and methodological factors influencing cost-effectiveness estimates and an assessment of study quality. RESULTS: A total of 14 studies were included for review. Considerable heterogeneity was found in terms of the methodologies used, HPV vaccination strategies evaluated and study quality. The reviewed studies generally supported the cost-effectiveness of HPV vaccine in China, although some reached alternative conclusions, particularly when assessed incremental to cervical cancer screening. Cost of vaccination was consistently identified as a key determinant for the cost-effectiveness of HPV vaccination programmes. CONCLUSIONS: Implementing HPV vaccination programmes should be complemented with expanded cervical cancer screening, while the release of lower-priced domestic vaccine offers more promising potential for initiating public HPV vaccination programmes. Findings of this study contributes important evidence for policies for cervical cancer prevention in China and methodological implications for future modelling efforts.
format Online
Article
Text
id pubmed-8655525
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86555252021-12-27 Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies Shi, Wenchuan Cheng, Xiaoli Wang, Haitao Zang, Xiao Chen, Tingting BMJ Open Health Economics OBJECTIVES: China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be established. We summarised evidence on the cost-effectiveness of HPV vaccine in China. DESIGN: Systematic review and narrative synthesis DATA SOURCES: PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang Data were searched through 2 January 2021 ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Cost-effectiveness studies using a modelling approach focusing on HPV vaccination interventions in the setting of China were included for review. DATA EXTRACTION AND SYNTHESIS: We extracted information from the selected studies focusing on cost-effectiveness results of various vaccination programmes, key contextual and methodological factors influencing cost-effectiveness estimates and an assessment of study quality. RESULTS: A total of 14 studies were included for review. Considerable heterogeneity was found in terms of the methodologies used, HPV vaccination strategies evaluated and study quality. The reviewed studies generally supported the cost-effectiveness of HPV vaccine in China, although some reached alternative conclusions, particularly when assessed incremental to cervical cancer screening. Cost of vaccination was consistently identified as a key determinant for the cost-effectiveness of HPV vaccination programmes. CONCLUSIONS: Implementing HPV vaccination programmes should be complemented with expanded cervical cancer screening, while the release of lower-priced domestic vaccine offers more promising potential for initiating public HPV vaccination programmes. Findings of this study contributes important evidence for policies for cervical cancer prevention in China and methodological implications for future modelling efforts. BMJ Publishing Group 2021-12-08 /pmc/articles/PMC8655525/ /pubmed/34880019 http://dx.doi.org/10.1136/bmjopen-2021-052682 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Economics
Shi, Wenchuan
Cheng, Xiaoli
Wang, Haitao
Zang, Xiao
Chen, Tingting
Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
title Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
title_full Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
title_fullStr Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
title_full_unstemmed Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
title_short Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
title_sort cost-effectiveness of human papillomavirus vaccine in china: a systematic review of modelling studies
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655525/
https://www.ncbi.nlm.nih.gov/pubmed/34880019
http://dx.doi.org/10.1136/bmjopen-2021-052682
work_keys_str_mv AT shiwenchuan costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies
AT chengxiaoli costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies
AT wanghaitao costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies
AT zangxiao costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies
AT chentingting costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies